I'm LongbridgeAI, I can summarize articles.Intra-Cellular Therapies (ITCI) has completed its merger with Johnson & Johnson, valued at approximately $14.6 billion. The company notified the Nasdaq Stock Market on April 2, 2025, about its plans to delist its shares as it becomes a wholly-owned subsidiary. Following the merger, all previous directors resigned, and the company's bylaws were amended to align with Johnson & Johnson. ITCI's current market cap is $14.05 billion, with a year-to-date price performance of 56.54%.
Intra-Cellular Therapies ( (ITCI) ) has provided an announcement.
On April 2, 2025, Intra-Cellular Therapies notified the Nasdaq Stock Market of its merger completion and plans to delist its shares from the Nasdaq Global Select Market. This move is part of a broader change in control as the company becomes a wholly-owned subsidiary of Johnson & Johnson, with the merger valued at approximately $14.6 billion. Following the merger, all previous directors resigned, and the company’s certificate of incorporation and bylaws were amended to align with those of the acquiring entity.
More about Intra-Cellular Therapies
YTD Price Performance: 56.54%
Average Trading Volume: 3,485,964
Technical Sentiment Signal: Sell
Current Market Cap: $14.05B
For an in-depth examination of ITCI stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- Paramount Stock (NASDAQ:PARA) Gains Despite Planned Streaming Budget Cuts
- Ford Stock (NYSE:F) Gains, But Ford Kuga Drivers Concerned
- Intel Stock (NASDAQ:INTC) Slips as Lip-Bu Tan Declares “Bureaucracy Kills Innovation”
Disclaimer & DisclosureReport an Issue